Clinic
ST. John's Lutheran Hospital, INC.
ST. John's Lutheran Hospital, INC. was paid $1.33M by Medicaid between Jan 2018 and Dec 2024, across 172 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoST. JOHN'S LUTHERAN HOSPITAL, INC.
LIBBY, MT 59923
LIBBY, MT 59923
33aNPI1952312050assigned 08/11/2006
33bProvider typeRural Health Clinic/Center
28Total paid$1.33M
24GClaims294,923
24DCodes billed172
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Health Clinic/Center providers in Montana
Rank by total paid#1 of 43
Median peer was paid$0.00
This provider vs. median0.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,127 | $205K | |
| 2019 | 47,430 | $256K | |
| 2020 | 37,506 | $160K | |
| 2021 | 48,332 | $142K | |
| 2022 | 40,750 | $175K | |
| 2023 | 41,219 | $257K | |
| 2024incomplete | 27,559 | $138K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 9,845 | 8,830 | $274K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 12,994 | 9,391 | $222K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.6% | 4,690 | 4,295 | $102K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 7.5% | 5,060 | 1,889 | $100K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 5.8% | 2,627 | 2,418 | $78K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.2% | 5,465 | 4,359 | $70K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.7% | 3,496 | 2,735 | $63K |
| G0378 | Hospital observation service, per hour | 3.4% | 3,701 | 1,637 | $46K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 1,863 | 1,599 | $46K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.3% | 11,253 | 3,634 | $30K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 1,680 | 1,130 | $28K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1.7% | 4,539 | 3,596 | $23K |
160 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 5,709 | $20K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.4% | 2,817 | $18K |
| 80053 | Comprehensive metabolic panel | 1.0% | 14,550 | $14K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,943 | $12K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,546 | $12K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,754 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,885 | $10K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,400 | $10K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,850 | $8K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 345 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,658 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,942 | $7K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,584 | $7K |
| 87040 | <1% | 2,598 | $7K | |
| 84145 | <1% | 2,856 | $5K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 425 | $5K |
| 83605 | <1% | 5,657 | $5K | |
| 86140 | <1% | 5,235 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,792 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,548 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,299 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,091 | $3K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 678 | $3K |
| 90837 | Psychotherapy session, about an hour | <1% | 32 | $3K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 510 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,784 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,090 | $2K |
| 81001 | <1% | 4,962 | $2K | |
| 84703 | <1% | 1,999 | $2K | |
| 73630 | <1% | 574 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 365 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 266 | $2K |
| 84484 | <1% | 5,276 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 239 | $2K |
| 83690 | <1% | 3,658 | $2K | |
| 87186 | <1% | 1,116 | $2K | |
| 96376 | <1% | 1,335 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,615 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 185 | $1K |
| 81003 | <1% | 2,931 | $1K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,731 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,719 | $1K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 149 | $1K |
| 97161 | <1% | 1,045 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,263 | $962.94 |
| 73030 | <1% | 291 | $907.68 | |
| 82150 | <1% | 2,629 | $867.49 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 398 | $852.77 |
| 99442 | <1% | 17 | $845.40 | |
| 83880 | <1% | 1,081 | $840.71 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 682 | $827.14 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,090 | $800.85 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 421 | $780.51 |
| 82550 | <1% | 3,664 | $716.13 | |
| 83735 | <1% | 3,473 | $704.06 | |
| 80050 | General health panel | <1% | 256 | $697.43 |
| 85610 | <1% | 4,119 | $692.24 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,622 | $631.84 |
| 74021 | <1% | 197 | $627.87 | |
| 94760 | <1% | 1,415 | $618.82 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 229 | $613.94 |
| 99441 | <1% | 21 | $576.00 | |
| A9270 | Non-covered item or service | <1% | 15,710 | $520.97 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,147 | $512.86 |
| 73610 | <1% | 264 | $454.21 | |
| 12001 | <1% | 39 | $437.34 | |
| 80061 | Lipid panel | <1% | 1,076 | $403.90 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,954 | $400.11 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 875 | $389.22 |
| 82553 | <1% | 721 | $381.67 | |
| 85651 | <1% | 760 | $359.60 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,314 | $356.73 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 136 | $316.67 |
| 85027 | <1% | 755 | $311.02 | |
| 76830 | Ultrasound, transvaginal | <1% | 42 | $298.62 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 726 | $293.54 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 71 | $289.20 |
| 87503 | <1% | 71 | $289.16 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,430 | $286.30 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,487 | $282.67 |
| 85378 | <1% | 588 | $275.39 | |
| 93225 | <1% | 26 | $260.85 | |
| 85730 | <1% | 898 | $257.61 | |
| 87592 | <1% | 25 | $248.53 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,296 | $227.81 |
| 73502 | <1% | 60 | $221.99 | |
| 96367 | <1% | 104 | $201.29 | |
| 73130 | <1% | 87 | $188.81 | |
| 73564 | <1% | 199 | $187.86 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,436 | $186.60 |
| 90715 | <1% | 42 | $174.51 | |
| 93000 | <1% | 216 | $173.88 | |
| 84439 | <1% | 173 | $151.09 | |
| 93226 | <1% | 26 | $146.00 | |
| 97162 | <1% | 136 | $139.50 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 550 | $139.25 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,122 | $137.07 |
| 96127 | <1% | 503 | $135.86 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,568 | $126.19 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 127 | $125.97 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 511 | $124.09 |
| 84100 | <1% | 398 | $122.99 | |
| 87070 | <1% | 55 | $94.45 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 132 | $93.39 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 383 | $77.38 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 347 | $74.45 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 211 | $58.99 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 39 | $57.23 |
| 82248 | <1% | 136 | $47.28 | |
| 83550 | <1% | 30 | $45.90 | |
| 99217 | <1% | 19 | $40.98 | |
| 83540 | <1% | 29 | $36.90 | |
| J3490 | Unclassified drugs | <1% | 131 | $36.67 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,228 | $29.04 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 596 | $24.89 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 45 | $24.30 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 23 | $24.30 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 352 | $21.87 |
| 73110 | <1% | 61 | $20.83 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,148 | $20.76 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 78 | $7.19 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 26 | $3.36 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,095 | $1.54 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 535 | $0.00 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 90 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 92 | $0.00 |
| 97113 | 0% | 26 | $0.00 | |
| 86850 | 0% | 65 | $0.00 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 20 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 104 | $0.00 |
| 92523 | 0% | 20 | $0.00 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 0% | 13 | $0.00 |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 0% | 69 | $0.00 |
| 86901 | 0% | 79 | $0.00 | |
| 82728 | 0% | 40 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 12 | $0.00 |
| 83615 | 0% | 33 | $0.00 | |
| 88342 | 0% | 18 | $0.00 | |
| 64483 | 0% | 18 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 16 | $0.00 |
| 82010 | 0% | 136 | $0.00 | |
| 0100U | 0% | 145 | $0.00 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 696 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 260 | $0.00 |
| 76642 | 0% | 13 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 129 | $0.00 |
| 99204 | Doctor's office visit, new patient (more involved) | 0% | 74 | $0.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 25 | $0.00 |
| 86900 | 0% | 79 | $0.00 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 0% | 63 | $0.00 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 22 | $0.00 |
| 85007 | 0% | 105 | $0.00 | |
| 87400 | 0% | 37 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 74 | $0.00 |
| J2401 | Injection, chloroprocaine hydrochloride, per 1 mg | 0% | 87 | $0.00 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 0% | 13 | $0.00 |
| 72100 | 0% | 12 | $0.00 | |
| 71250 | 0% | 14 | $0.00 | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 0% | 20 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEONARD, JULIE (CFO)